Whalesbook
Client-Specific Headwinds Aur Margin Compression
Toh bhaiyo aur behno, Syngene International ka Q3 FY26 result aaya hai aur numbers thode down hain. Revenue mein 7% ka fall dikha hai constant currency terms mein. Iska seedha reason hai unke ek major client Zoetis ka inventory adjustment, jisne development aur manufacturing services ko khaasa affect kiya.
Iska asar EBITDA margins par bhi hua, jo thoda compress hokar 22.8% par aa gaye hain (previous year same period mein forex ke alawa 25.4% the). Margins par pressure kuch wajahon se hai - staff ki salary increment, naye facilities chalane ke liye zyada power expenses aur automation mein investments. Upar se, gratuity liability mein ₹58 crore ka extra charge bhi record hua tha.
Zoetis ki ek khaas drug, Librela, ki sales bhi 6% kam hui hai reports ke mutabik. Is puri situation ko dekhte hue, Syngene ne FY26 ke liye apna revenue guidance bhi kam kar diya hai, ab 3-5% decline expect kar rahe hain.
Strategic Capacity Expansion Aur Growth Avenues
Lekin company future ke liye ekdum ready hai aur strategy change kar rahi hai. Yeh log biologics aur clinical services mein kaafi tezi se expansion kar rahe hain. Mangaluru mein jo small molecules facility hai, woh ab aachi perform kar rahi hai aur upcoming quarters mein sales badha sakti hai. Sabse important, Stelis Biopharma se acquired Unit III facility (large molecules) mein partial operations start ho gaye hain, jismein abhi 8-kiloliter ki production line chal rahi hai (total 20-kiloliter capacity hai). Aur ek aur badi khabar ye hai ki Bayview biologics facility Q4 FY26 mein operational ho jayegi.
Zoetis ki demand kam hone se company ki original biologics facility mein kuch capacity available ho gayi hai, jise woh dusre market opportunities ke liye use karne ka plan kar rahe hain. Zoetis ke direct impact ko chhhod dein, toh company high single-digit se low double-digit growth expect kar rahi hai.
Company ka balance sheet bhi ekdum mazboot hai, around ₹900 crore ka net cash unke paas hai. Iske saath, woh Mangaluru mein peptide clinical capabilities bhi develop kar rahe hain aur clinical trials market mein bhi entry maar rahe hain, jo aane wale time mein growth ka ek bada source ban sakta hai.
Valuation Discount Aur Investor Opportunity
Abhi Syngene International ka stock CRDMO sector ke dusre players ke comparison mein discount par mil raha hai. FY28 ke liye projected Enterprise Value to EBITDA roughly 16 times hai. Jin investors ke paas patience hai aur jo long-term growth opportunities dekhte hain, unke liye yeh ek interesting entry point ho sakta hai.